VIDEO: OUTBACK trial shows no benefit of adjuvant chemotherapy in locally advanced cervical cancer
Click Here to Manage Email Alerts
In this video, Stephen C. Rubin, MD, professor and chief of the division of gynecologic oncology and Grotzinger-Raab Chair in Surgical Oncology at Fox Chase Cancer Center in Philadelphia, discussed the OUTBACK trial presented at the ASCO Annual Meeting.
In the international, phase 3, randomized trial, which was presented as a late-breaking abstract during a plenary session, investigators randomly assigned women with locally advanced or advanced stage cervical cancer standard cisplatin-based chemoradiation or standard cisplatin-based chemoradiation followed by adjuvant chemotherapy with four cycles of carboplatin and paclitaxel.
The researchers found no survival benefit with adjuvant chemotherapy after standard cisplatin-based chemoradiation and, unsurprisingly, more adverse events among those who received the additional four cycles of carboplatin and paclitaxel, Rubin said.
The conclusion is “an important one,” he noted, adding that it should not be part of people’s treatment regimens.
Collapse
Mileshkin LR, et al. Late-Breaking Abstract 3. Presented at: ASCO Annual Meeting (virtual meeting); June 4-8, 2021.
Read more about
Click Here to Manage Email Alerts